1. Home
  2. CRDL vs MITT Comparison

CRDL vs MITT Comparison

Compare CRDL & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

BUY

Current Price

$1.15

Market Cap

226.6M

Sector

Health Care

ML Signal

BUY

Logo AG Mortgage Investment Trust Inc.

MITT

AG Mortgage Investment Trust Inc.

SELL

Current Price

$5.40

Market Cap

245.5M

Sector

Real Estate

ML Signal

SELL

Company Overview

Basic Information
Metric
CRDL
MITT
Founded
2017
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
226.6M
245.5M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
CRDL
MITT
Price
$1.15
$5.40
Analyst Decision
Strong Buy
Buy
Analyst Count
6
6
Target Price
$8.42
★ $8.71
AVG Volume (30 Days)
★ 1.5M
423.9K
Earning Date
11-12-2026
11-03-2026
Dividend Yield
N/A
★ 17.52%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.01
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.69
P/E Ratio
★ N/A
$547.00
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$5.39
52 Week High
$2.34
$9.27

Technical Indicators

Market Signals
Indicator
CRDL
MITT
Relative Strength Index (RSI) 21.71 25.85
Support Level $0.96 N/A
Resistance Level $1.35 $8.00
Average True Range (ATR) 0.08 0.16
MACD -0.04 -0.02
Stochastic Oscillator 1.64 10.59

Price Performance

Historical Comparison
CRDL
MITT

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About MITT AG Mortgage Investment Trust Inc.

TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.

Share on Social Networks: